Kiltearn Partners LLP Purchases Shares of 94,871 Gilead Sciences, Inc. $GILD

Kiltearn Partners LLP acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 94,871 shares of the biopharmaceutical company’s stock, valued at approximately $11,986,000. Gilead Sciences comprises about 2.9% of Kiltearn Partners LLP’s holdings, making the stock its 12th biggest holding.

Other hedge funds also recently modified their holdings of the company. Persistent Asset Partners Ltd bought a new stake in Gilead Sciences during the 2nd quarter worth approximately $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC raised its position in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new position in Gilead Sciences in the 4th quarter valued at $26,000. Finally, Wealth Preservation Advisors LLC boosted its stake in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.9%

NASDAQ GILD opened at $146.12 on Friday. The stock has a fifty day moving average of $131.97 and a 200-day moving average of $136.59. The stock has a market capitalization of $181.18 billion, a P/E ratio of -54.73 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the prior year, the firm posted $2.01 earnings per share. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. On average, equities research analysts forecast that Gilead Sciences, Inc. will post -0.51 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is currently -122.85%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the sale, the chief financial officer owned 165,646 shares in the company, valued at $22,918,780.56. The trade was a 1.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the sale, the director owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This represents a 33.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 87,000 shares of company stock valued at $11,562,960. 0.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on GILD. Rothschild & Co Redburn decreased their target price on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Weiss Ratings downgraded shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a report on Wednesday, May 20th. Barclays lowered their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.